<Suppliers Price>

ILMOFOSINE

Names

[ CAS No. ]:
83519-04-4

[ Name ]:
ILMOFOSINE

Chemical & Physical Properties

[ Molecular Formula ]:
C26H56NO5PS

[ Molecular Weight ]:
525.76500

[ Exact Mass ]:
525.36200

[ PSA ]:
102.93000

[ LogP ]:
7.74150

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
JH4758000
CHEMICAL NAME :
3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
CAS REGISTRY NUMBER :
83519-04-4
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C26-H56-N-O5-P-S
MOLECULAR WEIGHT :
525.86

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
253 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
74 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
615 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
113 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Human Cells - not otherwise specified
DOSE/DURATION :
1 mg/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,5538,1983

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301

[ Precautionary Statements ]:
P301 + P310

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
22

[ RIDADR ]:
UN 2811 6.1/PG 3

[ RTECS ]:
JH4758000

Synthetic Route

Articles

Phase I trial of ilmofosine as a 24 hour infusion weekly.

Invest. New Drugs 13(3) , 205-10, (1995)

Ilmofosine, an ether lipid derivative of lysophosphatidylcholine has antineoplastic activity in vitro and in vivo. Maximum efficacy in preclinical models is associated with prolonged exposure to the d...

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.

Invest. New Drugs 14(2) , 219-22, (1996)

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and ...

Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.

Lipids 28(6) , 511-6, (1993)

This investigation was initiated in order to delineate the structure-function relationship of the anticancer alkyl-lysophospholipids and assess their degree of selective cytotoxicity toward neoplastic...


More Articles


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.